Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

ABSTRACT:

Background

Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate.

Methods

Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other bone turnover markers, bone mineral density (BMD), and relationships between early chan

SUBMITTER: Miller PD 

PROVIDER: S-EPMC5399468 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature